Although its efficacy in PDAC remains unknown, sotorasib, which targets the KRAS G12C mutation, has been developed and has shown anticancer activity in patients with KRAS-G12C-mutated non-small-cell lung cancers [99]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.